SELLAS Life Sciences To Present SLS009 Phase 1 Data From Acute Myeloid Leukemia Patients At The 2024 European School Of Haematology Conference
SELLAS Life Sciences To Present SLS009 Phase 1 Data From Acute Myeloid Leukemia Patients At The 2024 European School Of Haematology Conference
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that data from the acute myeloid leukemia cohort of patients in the Phase 1 dose-escalation study of SLS009 (formerly GFH009) will be presented in an oral presentation at the 2024 European School of Haematology Acute Leukaemias (ESH) Conference: 4th How to Diagnose and Treat Acute Leukaemias, taking place March 1-3, 2024, in Stockholm, Sweden.
專注於爲各種癌症適應症開發新療法的後期臨床生物製藥公司SELLAS Life Sciences Group, Inc.（納斯達克股票代碼：SLS）（“SELLAS” 或 “公司”）今天宣佈，SLS009（前身爲 GFH009）1期劑量遞增研究中急性髓系白血病患者群體的數據將在2024年歐洲學院的口頭陳述中公佈血液學急性白血病（ESH）會議：第四屆如何診斷和治療急性白血病，將於2024年3月1日至3日在瑞典斯德哥爾摩舉行。
The presentation details are below:
演示詳情如下：
Title: Phase 1 Dose-Escalation Study of GFH009 in Acute Myeloid Leukemia
Session Date and Time: Sunday, March 3, 2024, at 12 pm CET
Session Title: Leukemia Treatment Challenges
Presenter: Dr. Tapan Kadia, Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas
Abstract Number: 6192705
標題：GFH009 治療急性髓系白血病的 1 期劑量遞增研究
會議日期和時間：歐洲中部時間 2024 年 3 月 3 日星期日中午 12 點
會議標題：白血病治療的挑戰
主持人：塔潘·卡迪亞博士，德克薩斯大學白血病系教授，德克薩斯州休斯敦醫學博士安德森癌症中心
摘要編號：6192705
